RepliCel Life Sciences Inc.
Save
2.75B
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss.

Similar securities

Based on sector and market capitalization

Report issue